TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03547674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: barefoot
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shoes only
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: untuned AFO with shoes
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tuned AFO with shoes
Description: Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
Study: NCT04185766

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Administration of a placebo solution (0.5 ml / kg)
Description: 43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (0.5 ml / kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Administration of a placebo solution (1 ml / kg)
Description: 43 newborns at risk of hypoglycaemia to which a placebo solution will be administered (1 ml / kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of 40% glucose in gel (0.5 ml / Kg)
Description: 43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (0.5 ml / Kg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Administration of 40% glucose in gel 1 ml / Kg)
Description: 43 newborns at risk of hypoglycaemia to which a solution of dextrose 40% in gel will be administered (1 ml / Kg).
Study: NCT00988949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spiradoline
Description: Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
Study: NCT04018716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MTA
Description: Indirect capping with MTA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dycal
Description: Indirect capping with Dycal
Study: NCT03400202

Intervention type: DEVICE
Intervention: Skin imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
Study: NCT03839966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification for Loneliness
Description: Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard \& Amir, 2008 and Beard, Weisberg, \& Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Habits Psychoeducation and Relaxation
Description: Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
Study: NCT01660425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancement with psychosocial intervention
Study: NCT03613233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma surgery
Description: phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma surgery
Description: phacoemulsification
Study: NCT03352739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the fornix, power on
Description: DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS of the NbM, power on
Description: DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS of the fornix, power off
Description: DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS of the NbM, power off
Description: DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead
Study: NCT01994785

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnographic Monitoring
Description: Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnographic Monitoring
Description: Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnographic Monitoring
Description: Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnographic Monitoring
Description: Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
Study: NCT03251001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
Study: NCT06489210

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: popliteal block
Description: using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: popliteal block
Description: using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: popliteal block
Description: using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
Study: NCT03700502

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional Magnetic Resonance Imaging
Description: The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional Magnetic Resonance Imaging
Description: The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional Magnetic Resonance Imaging
Description: The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
Study: NCT02351661

Intervention type: OTHER
Intervention: There was no intervention
Description: observational study, no intervention
Study: NCT04834609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of autologous adipose tissue in anal fistula
Study: NCT04012567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device: Biosure Regenesorb Interference Screw
Description: The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control device: BIOSURE HA Interference Screw
Description: BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
Study: NCT01694225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bubble packaging for monthly prescription
Description: Monthly bubble packaging among women prescribed anti-estrogens
Study: NCT03835702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAM Clinic Intervention
Description: SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
Study: NCT00988949

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: spiradoline
Description: Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04455242
Description: Single 30 mg oral dose of PF-04455242.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spiradoline
Description: Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
Study: NCT00966212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parent education
Description: Especially for Daughters audio-cd parent education
Study: NCT04347382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honey
Description: 1gm/Kg/Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa / Black Cumin
Description: 80mg/Kg/day
Study: NCT01034774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACHN-490 Injection
Description: ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
Study: NCT00209053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass
Study: NCT01846078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical biometric measurement (IOLMaster)
Description: IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
Study: NCT03042143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord derived CD362 enriched MSCs
Description: Infusion of Human umbilical cord derived CD362 enriched MSCs

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Plasma-Lyte 148)
Description: Infusion of placebo
Study: NCT03749278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Latina Friends Motivating the Soul (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Latina Friends Motivating the Soul (ALMA)
Description: In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
Study: NCT02108314

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Screening and Counselling
Description: The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
Study: NCT01755455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule
Study: NCT02744196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellbia
Description: Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Acellbia
Description: Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will look identical to the Acellbia solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT01207453

Intervention type: DRUG
Group type: OTHER
Intervention: Milnacipran
Description: Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Milnacipran
Description: Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT04093050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasostrict Injectable Product
Description: Vasostrict® (vasopressin injection, USP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasostrict Injectable Product
Description: Vasostrict® (vasopressin injection, USP)
Study: NCT01334606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 mm x 32G pen needle (Nano)
Description: The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8mm x 31G pen needle (Short)
Description: The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
Study: NCT04806659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH1573 Capsules
Description: Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Study: NCT03376763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify maintena
Description: Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify maintena
Description: Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
Study: NCT02735005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMAF assessment
Description: After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)
Study: NCT02452567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate (8-10%) diet-induced weight loss
Description: MAL participants will meet with the study dietitian to lose \~8-10% of their body weight through diet-intervention.
Study: NCT00193050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study: NCT02744196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Study: NCT01318148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: Intermittent intravenous application of caspofungin
Study: NCT01771159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBC
Description: The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor \[bladder\] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder.
Study: NCT01711125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 30mg/day
Description: 30mg/day 10 mg t.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 75mg/day
Description: 75mg/day 25 mg t.i.d
Study: NCT03400202

Intervention type: DEVICE
Intervention: Skin imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).

Intervention type: DEVICE
Intervention: Skin imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).

Intervention type: DEVICE
Intervention: Skin imaging
Description: Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).

Intervention type: OTHER
Intervention: Facial cleanser
Description: Facial cleanser prior to procedures.

Intervention type: OTHER
Intervention: Facial cleanser
Description: Facial cleanser prior to procedures.

Intervention type: OTHER
Intervention: Facial cleanser
Description: Facial cleanser prior to procedures.

Intervention type: OTHER
Intervention: Facial cleanser
Description: Facial cleanser prior to procedures.
Study: NCT01711125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 3 matched tabs/day
Study: NCT04347382

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Empty capsule with 250ml of distilled water